Clinical and Immunologic Effects of Monthly Administration of Intravenous Cyclophosphamide in Severe Systemic Lupus Erythematosus

New England Journal of Medicine

Volumn 318, Issue 22, 1988, Pages 1423-1431

  McCune, W Joseph ^a   Golbus, Joseph ^a   Zeldes, Wendy ^a   Bohlke, Patricia ^a   Dunne, Robert ^a   Fox, David A ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE;

ADULT; CLINICAL ARTICLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

EID: 0023889565     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM198806023182203     Document Type: Article

References (52)

1. Blaese RM, Grayson J, Steinberg AD. Increased immunoglobulin-secreting cells in the blood of patients with systemic lupus erythematosus. Am J Med 1980; 69: 345–50.
2. Balow JE, Tsokos GC. T and B lymphocyte function in patients with lupus nephritis: correlation with renal pathology. Clin Nephrol 1984; 21: 93–7.
3. Lipnick RN, Balow JE, Tsokos GC. Lymphocyte subpopulations in patients with systemic lupus erythematosus. Clin Immunol Immunopathol 1984; 31: 181–90.
4. Morimoto C, Reinherz EL, Schlossman SF, Schur PH, Mills JA, Steinberg AD. Alterations in immunoregulatory T cell subsets in active systemic lupus erythematosus. J Clin Invest 1980; 66: 1171–4.
5. Bakke achéal, Kirkland PA, Kitridou RC, et al. T lymphocyte subsets in systemic lupus erythematosus: correlations with corticosteroid therapy and disease activity. Arthritis Rheum 1983; 26: 745–50.
6. Cohen PL, Litvin DA, Winfield JB. Association between endogenously activated T cells and immunoglobulin-secreting B cells in patients with active systemic lupus erythematosus. Arthritis Rheum 1982; 25: 168–73.
7. Gottlieb AB, Lahita RG, Chiorazzi N, Kunkel HG. Immune function in systemic lupus erythematosus: impairment of in vitro T-cell proliferation and in vivo antibody response to exogenous antigen. J Clin Invest 1979; 63: 885–92.
8. Linker-Israeli M, Bakke achéal, Quismorio FP Jr, Horwitz DA. Correction of interleukin-2 production in patients with systemic lupus erythematosus by removal of spontaneously activated suppressor cells. J Clin Invest 1985; 75: 762–8.
9. Miyasaka N, Nakamura T, Russell IJ, Talal N. Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 1984; 31: 109–17.
10. Sakane T, Steinberg AD, Green I. Failure of autologous mixed lymphocyte reactions between T and non-T cells in patients with systemic lupus erythematosus. Proc Natl Acad Sci USA 1978; 75: 3464–8.
11. Wallace DJ, Podell T, Weiner DPG, Klinenberg JR, Forouzesh S, Dubois EL. Systemic lupus erythematosus — survival patterns: experience with 609 patients. JAMA 1981; 245: 934–8.
12. Balow JE, Austin HA III, Meunz LR, et al. Effect of treatment on the evolution of renal abnormalities in lupus nephritis. N Engl J Med 1984; 311: 491–5.
13. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med 1978; 299: 1151–5.
14. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986; 314: 614–9.
15. Hahn BH, Kantor OS, Osterland CK. Azathioprine plus prednisone compared with prednisone alone in the treatment of systemic lupus erythematosus: report of a prospective controlled trial in 24 patients. Ann Intern Med 1975; 83: 597–605.
16. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis: results of a pooled analysis. N Engl J Med 1984; 311: 1528–33.
17. Dinant HJ, Decker JD, Klippel JH, Balow JE, Plotz PH, Steinberg AD. Alternative modes of cyclophosphamide and azathioprine therapy in lupus nephritis. Ann Intern Med 1982; 96: 728–36.
18. Donadio JV Jr, Holley KE, Wagoner RD, Ferguson RH, McDuffie FC. Treatment of lupus nephritis with prednisone and combined prednisone and azathioprine. Ann Intern Med 1972; 77: 829–35.
19. Steinberg AD, Kaltreider HB, Staples PJ, Goetzl EJ, Talal N, Decker JL. Cyclophosphamide in lupus nephritis: a controlled trial. Ann Intern Med 1971; 75: 165–71.
20. Carette S, Klippel JH, Decker JL, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis: a long-term follow-up. Ann Intern Med 1983; 99: 1–8.
21. Balow JE, Austin HA III, Tsokos G, Antonovych TT, Steinberg AD, Klippel JH. Lupus nephritis. Ann Intern Med 1987; 106: 79–94.
22. Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol 1982; 128: 2453–7.
23. Chiorazzi N, Fox DA, Katz DH. Hapten-specific IgE antibody responses in mice. VI. Selective enhancement of IgE antibody production by low doses of X-irradiation and by cyclophosphamide. J Immunol 1976; 117: 1629–37.
24. Ozer H Jr, Cowens JW, Colvin M, Nussbaum-Blumenson A, Sheedy D. In vitro effects of 4-hydroperoxycyclophosphamide on human immunoregulatory T subset function. I. Selective effects on lymphocyte function in T-B cell collaboration. J Exp Med 1982; 155: 276–90.
25. Bast RC Jr, Reinherz EL, Maver C, Lavin P, Schlossman SF. Contrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes. Clin Immunol Immunopathol 1983; 28: 101–14.
26. Colvin M, Hilton J. Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep 1981; 65: Suppl 3: 89–95.
27. Cox PJ. Cyclophosphamide cystitis — identification of acrolein as the causative agent. Biochem Pharmacol 1979; 28: 2045–9.
28. Plotz PH, Klippel JH, Decker JL. Bladder complications in patients receiving cyclophosphamide for systemic lupus erythematosus or rheumatoid arthritis. Ann Intern Med 1979; 91: 221–3.
29. Tan EM, Cohen AS, Fries J, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271–7.
30. Austin HA III, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med 1983; 75: 382–91.
31. Pincus T, Schur PH, Rose JA, Decker JL, Talal N. Measurement of serum DNA-binding activity in systemic lupus erythematosus. N Engl J Med 1969; 281: 701–5.
32. Kent JF, Fife EH Jr. Precise standardization of reagents for complement fixation. Am J Trop Med Hyg 1963; 12: 103–16.
33. Meuer SC, Hussey RE, Hodgdon JC, Hercend T, Schlossman SF, Reinherz EL. Surface structures involved in target recognition by human cytotoxic T lymphocytes. Science 1982; 218: 471–3.
34. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678–85.
35. Hercend T, Griffin JD, Bensussan A, et al. Generation of monoclonal antibodies to a human natural killer clone: characterization of two natural killer-associated antigens, NKHIA and NKH2, expressed on subsets of large granular lymphocytes. J Clin Invest 1985; 75: 932–43.
36. Meuer SC, Hussey RE, Cantrell DA, et al. Triggering of the T3–Ti antigen–receptor complex results in clonal T-cell proliferation through an interleukin 2-dependent autocrine pathway. Proc Natl Acad Sci USA 1984; 81: 1509–13.
37. Meuer SC, Hussey RE, Fabbi M, et al. An alternative pathway of T-cell activation: a functional role for the 50 kd T11 sheep erythrocyte receptor protein. Cell 1984; 36: 897–906.
38. Meuer SC, Hodgdon JC, Hussey RE, Protentis JP, Schlossman SF, Reinherz EL. Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones. J Exp Med 1983; 158: 988–93.
39. Clement LT, Tilden AB, Dunlap NE. Analysis of the monocyte Fc receptors and antibody-mediated cellular interactions required for the induction of T cell proliferation by anti-T3 antibodies. J Immunol 1985; 135: 165–71.
40. Hara T, Fu SM. Human T cell activation. I. Monocyte-independent activation and proliferation induced by anti-T3 monoclonal antibodies in the presence of tumor promoter 12-o-tetradecanoyl phorbol-13 acetate. J Exp Med 1985; 161: 641–56.
41. Leca G, Boumsell L, Fabbi M, Reinherz EL, Kanellopoulos JM. The sheep erythrocyte receptor and both α and β chains of the human T-lymphocyte antigen receptor bind the mitogenic lectin (phytohaemagglutinin) from Phaseolus vulgaris. Scand J Immunol 1986; 23: 535–44.
42. Fox DA, Schlossman SF, Reinherz EL. Regulation of the alternative pathway of T cell activation by anti-T3 monoclonal antibody. J Immunol 1986; 136: 1945–50.
43. Yang SY, Chouaib S, Dupont B. A common pathway for T lymphocyte activation involving both the CD3-Ti complex and CD2 sheep erythrocyte receptor determinants. J Immunol 1986; 137: 1097–100.
44. Fox DA, Hussey RE, Fitzgerald DA, et al. Activation of human thymocytes via the 50KD Tl1 sheep erythrocyte binding protein induces the expression of interleukin 2 receptors on both T3+ and T3- populations. J Immunol 1985; 134: 330–5.
45. O'Flynn K, Krensky AM, Beverley PCL, Burakoff SJ, Linch DC. Phyto-haemagglutinin activation of T cells through the sheep red blood cell receptor. Nature 1985; 313: 686–7.
46. Selvaraj P, Plunkett ML, Dustin M, Sanders ME, Shaw S, Springer TA. The T lymphocyte glycoprotein CD2 binds the cell surface ligand LFA-3. Nature 1987; 326: 400–3.
47. Peterson A, Seed B. Monoclonal antibody and ligand binding sites of the T cell erythrocyte receptor (CD2). Nature 1987; 329: 842–6.
48. Sayre PH, Chang H-C, Hussey RE, et al. Molecular cloning and expression of Tl1 cDNAs reveal a receptor-like structure on human T lymphocytes. Proc Natl Acad Sci USA 1987; 84: 2941–5.
49. Seed B. An LFA-3 cDNA encodes a phospholipid-linked membrane protein homologous to its receptor CD2. Nature 1987; 329: 840–2.
50. Vollger LW, Tuck DT, Springer TA, Haynes BF, Singer KH. Thymocyte binding to human thymic epithelial cells is inhibited by monoclonal antibodies to CD-2 and LFA-3 antigens. J Immunol 1987; 138: 358–63.
51. Juy D, Sterkers G, Bernard A, Levy JP. Frequency analysis of human peripheral blood B cells sensitive to CD2 monoclonal antibody-activated T cells. Human Immunol 1987; 19: 225–33.
52. Moody DJ, Kagan J, Liao D, Ellison GW, Meyers LW. Administration of monthly-pulse cyclophosphamide in multiple sclerosis patients: effects of long-term treatment on immunologic parameters. J Neuroimmunol 1987; 14: 161–73.